143 related articles for article (PubMed ID: 20825052)
1. [Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients].
Grzybowski W; Beta J; Fritz A; Durczyński A; Bidziński M; Grabiec M; Jakimiuk AJ
Ginekol Pol; 2010 Jul; 81(7):511-5. PubMed ID: 20825052
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses.
Tanir HM; Ozalp S; Yalcin OT; Colak O; Akcay A; Senses T
Eur J Gynaecol Oncol; 2003; 24(3-4):271-4. PubMed ID: 12807238
[TBL] [Abstract][Full Text] [Related]
3. [Association of ovarian tumors with CA-125].
Martínez-Acosta JE; Olguín-Cruces VA
Rev Med Inst Mex Seguro Soc; 2016; 54 Suppl 3():S230-S237. PubMed ID: 27855043
[TBL] [Abstract][Full Text] [Related]
4. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of the morphological ultrasound score system and the serum concentration of CA 125 in the diagnosis of malignant ovarian cancer].
Brazert J; Pietryga M; Szabłoński W; Persona-Sliwińska A; Biczysko R
Ginekol Pol; 2003 Dec; 74(12):1542-8. PubMed ID: 15029747
[TBL] [Abstract][Full Text] [Related]
6. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
7. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
9. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
10. Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
Chudecka-Głaz A; Cymbaluk-Płoska A; Jastrzębska J; Menkiszak J
Tumour Biol; 2016 Jul; 37(7):8879-87. PubMed ID: 26753953
[TBL] [Abstract][Full Text] [Related]
11. Sonographic discrimination between benign and malignant adnexal masses in premenopause.
Radosa MP; Vorwergk J; Fitzgerald J; Kaehler C; Schneider U; Camara O; Runnebaum IB; Schleußner E
Ultraschall Med; 2014 Aug; 35(4):339-44. PubMed ID: 23775448
[TBL] [Abstract][Full Text] [Related]
12. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.
Van Calster B; Timmerman D; Bourne T; Testa AC; Van Holsbeke C; Domali E; Jurkovic D; Neven P; Van Huffel S; Valentin L
J Natl Cancer Inst; 2007 Nov; 99(22):1706-14. PubMed ID: 18000221
[TBL] [Abstract][Full Text] [Related]
13. [HE4 a biomarker of ovarian cancer].
Presl J; Kučera R; Topolčan O; Novotný Z; Vrzalová J; Fuchsova R; Betincová L; Rokyta Z
Ceska Gynekol; 2012 Oct; 77(5):445-9. PubMed ID: 23116350
[TBL] [Abstract][Full Text] [Related]
14. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
15. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Cane P; Azen C; Lopez E; Platt LD; Karlan BY
Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
[TBL] [Abstract][Full Text] [Related]
16. HE4 and ROMA index in Czech postmenopausal women.
Novotny Z; Presl J; Kucera R; Topolcan O; Vrzalova J; Fuchsova R; Betincova L; Rokyta Z
Anticancer Res; 2012 Sep; 32(9):4137-40. PubMed ID: 22993374
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of clinical evaluation for the level of CA-125 antigen and ultrasonographic color Doppler examination in diagnosis of ovarian tumor].
Czekierdowski A; Zrubek H; Sikorski M; Wiktor H; Józefczak M; Stachowicz N
Ginekol Pol; 1996 Nov; 67(11):552-6. PubMed ID: 9289441
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
19. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening.
Roupa Z; Faros E; Raftopoulos V; Tzavelas G; Kotrotsiou E; Sotiropoulou P; Karanikola E; Skifta E; Ardavanis A
In Vivo; 2004; 18(6):831-6. PubMed ID: 15646829
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing serum CA125II levels in healthy postmenopausal women.
Pauler DK; Menon U; McIntosh M; Symecko HL; Skates SJ; Jacobs IJ
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):489-93. PubMed ID: 11352859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
